公开(公告)号：US20110118258A1

公开(公告)日：2011-05-19

申请号：US12599116

申请日：2008-05-15

申请人： Stephen Martin Courtney ,  Mark Whittaker ,  Owen Clifford Mather ,  Christopher John Yarnold ,  Oliver Robin Barker ,  Christian Aldo Georges Napoleon Montalbetti ,  Thomas Hesterkamp ,  Mihaly Daniel Gardiner

发明人： Stephen Martin Courtney ,  Mark Whittaker ,  Owen Clifford Mather ,  Christopher John Yarnold ,  Oliver Robin Barker ,  Christian Aldo Georges Napoleon Montalbetti ,  Thomas Hesterkamp ,  Mihaly Daniel Gardiner

IPC分类号： A61K31/517 ,  C07D239/84 ,  C07D413/12 ,  C07D409/08 ,  C07D405/10 ,  C07D401/10 ,  C07D403/10 ,  C07D403/12 ,  A61K31/5377 ,  A61P35/00 ,  A61P29/00 ,  A61P31/12

CPC分类号： C07D239/84 ,  C07D401/04 ,  C07D403/10 ,  C07D405/04 ,  C07D409/04

摘要： Compounds of general formula (I); or a stereoisomers, tautomers, pharmaceutically acceptable salts, or prodrugs thereof, wherein R1, R2, R3, R4, R5, R6, R8 and R9 are as defined herein, are useful for the treatment of diseases and conditions which are mediated by excessive or inappropriate Hsp90 activity such as cancers, viral infection and inflammatory diseases or conditions.

摘要翻译： 通式（I）的化合物; 或其立体异构体，互变异构体，药学上可接受的盐或前药，其中R 1，R 2，R 3，R 4，R 5，R 6，R 8和R 9如本文所定义，可用于治疗疾病和病症， 不适当的Hsp90活动如癌症，病毒感染和炎性疾病或病症。

公开(公告)号：US08592430B2

公开(公告)日：2013-11-26

申请号：US12599116

申请日：2008-05-15

申请人： Stephen Martin Courtney ,  Mark Whittaker ,  Owen Clifford Mather ,  Christopher John Yarnold ,  Oliver Robin Barker ,  Christian Aldo Georges Napoleon Montalbetti ,  Thomas Hesterkamp ,  Mihaly Daniel Gardiner

发明人： Stephen Martin Courtney ,  Mark Whittaker ,  Owen Clifford Mather ,  Christopher John Yarnold ,  Oliver Robin Barker ,  Christian Aldo Georges Napoleon Montalbetti ,  Thomas Hesterkamp ,  Mihaly Daniel Gardiner

IPC分类号： A61K31/517 ,  A61K31/519 ,  C07D239/84

CPC分类号： C07D239/84 ,  C07D401/04 ,  C07D403/10 ,  C07D405/04 ,  C07D409/04

摘要： Compounds of general formula (I); or a stereoisomers, tautomers, pharmaceutically acceptable salts, or prodrugs thereof, wherein R1, R2, R3, R4, R5, R6, R8 and R9 are as defined herein, are useful for the treatment of diseases and conditions which are mediated by excessive or inappropriate Hsp90 activity such as cancers, viral infection and inflammatory diseases or conditions.

摘要翻译： 通式（I）的化合物; 或其立体异构体，互变异构体，药学上可接受的盐或前药，其中R 1，R 2，R 3，R 4，R 5，R 6，R 8和R 9如本文所定义，可用于治疗疾病和病症， 不适当的Hsp90活动如癌症，病毒感染和炎性疾病或病症。